Facebook
Twitter
LinkedIn
ForwardTitle
Category
Credits
Event date
Cost
- LivDerm
- TME
- AMA PRA Category 1 Credit™
- ANCC
- Participation
$0.00
Pediatric patients with skin of color (SoC) can be disproportionately affected by a number of dermatologic conditions, including acne vulgaris, atopic dermatitis, and traction alopecia. It is imperative that providers are able to recognize and appropriately treat these conditions in their pediatric SoC patients. Going beyond basic treatment guidelines, there are steps clinicians can be taking to practice cultural sensitivity when treating patients and communicating with parents and caregivers.
- LivDerm
- TME
- AMA PRA Category 1 Credit™
- ANCC
- Participation
$0.00
Atopic dermatitis (AD) is a chronic inflammatory and relapsing cutaneous disease characterized by pruritus, cutaneous inflammation, and transepidermal water loss (Krakowski 2008). The incidence of AD in industrialized nations has increased by three-fold over a 30-year span, and it is estimated to affect between 15% and 30% of children in industrialized nations (Bieber 2010). Although most children with AD will “outgrow” the disease, AD has additionally been reported to affect up to 10% of adults, and recent research suggests that AD is under-recognized in this group (Bieber 2010; Silverbe
- LivDerm
- TME
- AMA PRA Category 1 Credit™
- ANCC
- Participation
$0.00
Alopecia areata (AA) is an autoimmune disease that results in hair loss on the scalp and body. Currently,there is no FDA approved treatment for alopecia areata, challenging clinicians to find effectivetreatments in practice. However, recent findings have furthered understanding of AA, including thetargeting of specific immunologic pathways. Multiple clinical studies are underway investigating the useof Janus kinase (JAK) and TEC-family kinase inhibitors for treatment of moderate-to-severe AA.
- LivDerm
- TME
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- Participation
$0.00
Melanoma can be a life-threatening condition if left untreated. Patients with skin of color often face delays in diagnosis and treatment initiation in melanoma care. These disparities point to the need for increased awareness and education on melanoma risk and identification for clinicians and patients. Immunotherapies as mono and combination therapeutic regimens have become the gold standard in melanoma management.
- CMHC
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- Participation
$0.00
Addressing iron deficiency (ID) in patients with heart failure (HF) has become an important aspect of optimizing guideline-directed care in HF, as outlined by recent evidence and updated guidelines. During this webinar, expert faculty utilize challenging cases to discuss the importance of addressing ID in HF, as well as practical considerations for the diagnosis and treatment of ID in this setting.
- CMHC
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- Participation
$0.00
Iron deficiency (ID) with or without anemia is a common and important comorbidity in patients with heart failure (HF), and it can have significant impacts on morbidity and mortality. Despite this burden, the diagnosis and assessment of ID is not widely sought by clinicians that see patients with HF, leading to underdiagnosis, misdiagnosis, and delayed treatment. Recent trials and evidence have shown that i.v. iron repletion in HF patients with ID can improve symptoms, quality of life, and outcomes, and this evidence has been reflected accordingly in the updated HF guidelines.
- LivDerm
- TME
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- Participation
$0.00
Psoriatic arthritis (PsA) is a chronic, debilitating inflammatory disease that is associated with several comorbidities and often antecedes psoriasis. In fact, according to data from the National Psoriasis Foundation (NPF), approximately 30% of people with psoriasis develop PsA, with symptoms appearing around 10 years after the occurrence of cutaneous symptoms.
- CMHC
- TME
$0.00
The increasing prevalence and impacts of overweight and obesity in patients with type 2 diabetes renders weight loss and weight loss maintenance an important part of treatment goals. In this 6-part webcast series, chaired by Robert H. Eckel, MD and Donna Ryan, MD, you will have a chance to hear from experts on the comprehensive management of obesity in patients with type 2 diabetes, including lifestyle modifications, the spectrum of pharmacotherapy and metabolic surgery, as well as how to practically apply these concepts to patient care.
- CMHC
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- CDE
- Participation
$0.00
Expert faculty developed three challenging cases that illustrate practical points about the current challenges of optimizing LDL-C lowering therapy, as well as how to optimize treatment with statin and non-statin therapies. In addition, the cases serve to offer clinical pearls on how the newer therapies fit into the treatment landscape and inform patient selection. During the webcast, expert faculty engage in interactive discussions to offer additional perspectives and clinical pearls.
- CMHC
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- CDE
- Participation
$0.00
Expert faculty developed challenging cases to illustrate practical points in the optimization of LDL-C therapy post-MI, including, but not limited to the points illustrated below. At the end of each case, faculty engage in discussions to offer clinical pearls and expert insights on the cases.